August 3, 2017 — Researchers presented clinical data supporting use of the Xoft Axxent Electronic Brachytherapy (eBx) System for the treatment of endometrial cancer at the American Association of Physicists in Medicine (AAPM) Annual Meeting & Exhibition, July 30-Aug. 3 in Denver. iCAD also showcased its multi-platform Xoft System and related suite of products at its booth during the meeting.
Researchers from Miguel Servet University Hospital in Zaragoza, Spain presented preliminary findings from their recent clinical experience treating 36 endometrial cancer patients with electronic brachytherapy using the Xoft System at the AAPM meeting. The dosimetric analysis showed that electronic brachytherapy with the Xoft System delivered a lower dose of radiation to surrounding healthy organs at risk in patients with endometrial cancer, such as the bladder and rectum, than would have been delivered by radiation therapy treatment with Ir-192 or Co-60 sources.
“By precisely targeting cancer cells and sparing surrounding healthy tissue and organs, the Xoft System can successfully treat endometrial cancer while reducing the risk of exposure to surrounding tissue,” said Sergio Lozares, M.D., medical physicist at Miguel Servet University Hospital. “We are encouraged by these early results demonstrating that the Xoft System can be a clinically valuable treatment option for appropriate patients.”
The Xoft System is U.S. Food and Drug Administration (FDA)-cleared, CE marked and licensed in a growing number of countries for the treatment of cancer anywhere in the body, including early-stage breast cancer, gynecological cancers and non-melanoma skin cancer.
For more information: www.xoftinc.com
April 25, 2024 
